A Phase 1b/2, Open Label, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacodynamics and Antitumor Activity of GX-I7 in Combination With Pembrolizumab in Subjects With Refractory or Relapsed (R/R) TNBC
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 29 Nov 2018
At a glance
- Drugs GX I7 (Primary) ; Pembrolizumab (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms KEYNOTE-899
- Sponsors Genexine
- 29 Nov 2018 Status changed from planning to not yet recruiting.
- 24 Jul 2018 New trial record
- 18 Jul 2018 According to a Genexine media release, this trial is being supported by grant from the Korea Drug Development Fund (KDDF).